Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Specificity: Oncogenic protein Her-2/neu (erbB-2), a member of the family of epidermal growth factor (EGF) receptors, overexpressed in 30% of invasive breast cancers and 70% of ductal carcinomata in situ, in a small percentage of melanomas, and in other malignancies originating from various organs, including ovary, kidney, colon, and bladder.
Trastuzumab with the brand name Herceptin, is an FDA-approved drug for HER2-targeted therapy for breast cancer. It is a recombinant humanized monoclonal antibody (IgG1 kappa). Trastuzumab binds to HER2 receptor present on the surface of HER2-positive tumour cells and suppresses the cells growth and proliferation.
仅用于科研。不用于诊断过程。未经明确授权不得转售。